Maintenance chemotherapy showed no clear difference in 3‐year OS compared with observation (moderate certainty).
Maintenance chemotherapy showed no clear difference in 5‐year OS compared with observation (moderate certainty).
Maintenance chemotherapy showed no clear difference in 10‐year OS compared with observation (moderate certainty).
Chemotherapy with bevacizumab leads to lower overall survival (OS) compared with chemotherapy alone (high certainty).
Chemotherapy with bevacizumab probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).
The review found no eligible studies for this question.
Chemotherapy with bevacizumab showed no clear difference in any adverse event grade ≥ 3 compared with chemotherapy alone (low certainty).
Chemotherapy with bevacizumab may leads to higher hypertension (grade ≥ 2) compared with chemotherapy alone (low certainty).
Chemotherapy with bevacizumab showed no clear difference in bowel fistula / perforation (grade ≥ 2) compared with chemotherapy alone (low certainty).
Bevacizumab plus chemotherapy may leads to lower overall survival compared with chemotherapy (low certainty).
Bevacizumab plus chemotherapy probably leads to higher specificadverse events: gastrointestinal perforations or fistulae compared with chemotherapy (moderate certainty).
Bevacizumab plus chemotherapy may leads to higher specific adverse events: serious haemorrhage compared with chemotherapy (low certainty).
Bevacizumab plus chemotherapy probably leads to higher specific adverse events: serious thromboembolic events compared with chemotherapy (moderate certainty).
Bevacizumab plus chemotherapy probably leads to higher specific adverse events: hypertension compared with chemotherapy (moderate certainty).
Bevacizumab plus chemotherapy probably leads to higher serious adverse events compared with chemotherapy (moderate certainty).
Taxane‐containing chemotherapy leads to lower overall survival compared with any chemotherapy without taxane (high certainty).
Taxane‐containing chemotherapy leads to lower disease‐free progression compared with any chemotherapy without taxane (high certainty).
Taxane‐containing chemotherapy showed no clear difference in febrile neutropenia compared with any chemotherapy without taxane (moderate certainty).